Tweaking Brand-Name Drugs Can Hurt Competition, FTC Says
The Federal Trade Commission has told the Pennsylvania federal court considering a consolidated antitrust suit against Warner Chilcott PLC that minor, nontherapeutic changes to a branded drug can represent exclusionary conduct...To view the full article, register now.
Already a subscriber? Click here to view full article